Johns Hopkins' psilocybin smoking-cessation pilot study

The Johns Hopkins' psilocybin smoking-cessation pilot study tested whether psilocybin, given alongside cognitive behavioral therapy, might help smokers stop and remain abstinent. Its results were striking for a small preliminary trial: carbon-monoxide measurements confirmed that 80 percent of its fifteen volunteers were abstinent six months after their sessions, and 67 percent remained abstinent at one year. The study did not establish that psilocybin caused those outcomes, but it offered a notable signal—and a model of treatment in which preparation, psychotherapy, and the experience itself were entwined.

Origins and Research Context

The pilot grew out of a renewed research effort after sanctioned psychedelic therapy ended in the 1970s. Earlier investigators had explored psychedelics for alcohol dependence: work at the Saskatchewan Mental Hospital helped make LSD therapy a standard treatment option in the province, but a later replication attempt by the Addiction Research Foundation in Toronto produced worse outcomes under neutral, restrictive conditions. That contrast had already raised a lasting question for psychedelic research: whether a drug's apparent effect could be separated from the conditions and human relationships surrounding its use.

By the time the smoking study began, research at Johns Hopkins University had resumed under Roland Griffiths. Matthew Johnson, a psychologist who had trained as a behaviorist and studied topics including operant conditioning in rats, joined the Hopkins work after arriving for a pharmacology postdoctoral position in 2004. His interest in psychedelics dated to college, when he read Ram Dass and learned about the Harvard Psilocybin Project. At Hopkins he helped guide several dozen psilocybin sessions and analyze data from early studies before launching the smoking pilot in 2009.

Treatment Design

The study enrolled fifteen volunteer smokers who were trying to quit. Participants received several sessions of cognitive behavioral therapy, followed by two or three psilocybin doses. It was an open-label study: there was no placebo group, and everyone knew they were receiving psilocybin. Volunteers stopped smoking before their psilocybin session, and researchers measured carbon-monoxide levels at several intervals to check that they had stopped and to verify continued abstinence.

That design joined a behavioral treatment to a drug session rather than testing psilocybin in isolation. The result was a potentially important feature of the intervention, but also a limit on what the study could show: without randomization or a control group, it could not determine how much of the outcome came from psilocybin, cognitive behavioral therapy, participants' expectations, or the overall therapeutic process. More broadly, psychedelic trials are difficult to blind because participants and guides can often tell whether the active drug was given, while the effects of the drug may be inseparable from the setting and the people present.

Outcomes and the Role of Experience

Six months after the sessions, 80 percent of participants had biochemically confirmed abstinence. At the one-year mark, the rate was 67 percent. The decline over time mattered, but the remaining abstinence was still reported as exceeding the success rate of the best treatment then available. A larger randomized study comparing psilocybin therapy with the nicotine patch was under way, a step toward testing whether this early result would hold under more rigorous conditions.

The researchers also observed that volunteers reporting the most complete mystical experiences had the best outcomes. Charles Bessant, one of the study participants, had remained abstinent for six years when described in the account. His experience was presented as an example of a broader shift in perspective: smoking had become less consequential, rather than something he had to resist at every moment. That interpretation accords with the book's discussion of volunteers who gained distance from habits that had previously seemed difficult to escape. It does not, however, prove that mystical intensity produced abstinence; in a study this small, the association was a clue for further investigation, not a demonstrated mechanism.

Significance and Limits

The pilot's promise rested both on its reported rates and on the possibility that a powerful experience could alter how participants understood an entrenched habit. Yet its small sample, lack of random assignment, and absence of a placebo comparison make caution essential. Across early psychedelic studies, researchers and therapists may be unusually invested in success, participants are selected in small numbers, and the attention they receive can be difficult to reproduce at scale. The smoking results therefore stood as an encouraging signal, not proof of a broadly effective cure.

The study also exemplified a challenge running through the modern psychedelic research revival: treatment may depend on more than a molecule's pharmacological action. The therapeutic relationship, preparation, expectations, and environment can shape what participants experience, while making standard efforts to isolate a single causal variable more difficult. The pilot's contribution was consequently twofold: it put forward a promising approach to smoking cessation and made visible the methodological problem at its center—how to evaluate a treatment whose proposed action may include the meaning and circumstances of the experience itself.